26.01.2016 • News • Elaine Burridge • capacity expansion • Songwon

Songwon Starts Additives Production at Abu Dhabi

South Korea’s Songwon Industrial Group has announced the start-up of its joint venture additives plant in Abu Dhabi.

The 7,000 t/y facility is located in the Khalifa Industrial Zone and manufactures Songwon’s tailor-made additive blends, known as One Pack Systems (OPS). It is operated by Polysys Additive Technologies Middle East, the venture formed by Songwon with Polysys Industries and Pan Gulf Holding.

Songwon said the plant had been designed to allow for future expansion to meet increasing demand for OPS products in the Middle East and beyond. Maurizio Butti, Songwon’s chief operating officer, said the region was one of the fastest growing markets for polyolefins and already a major consumer of OPS.

Hans Daniels, general manager of Polysys Additive Technologies, added that Khalifa enjoyed a unique location with its port facilities and infrastructure, and was a very effective hub for supplying customers across the entire region.

The Abu Dhabi facility adds to Songwon’s existing OPS production in Greiz, Germany, and Houston, Texas, US.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.